ClinicalTrials.gg
Not yet recruitingNCT07685275RespireUpdated Jul 6, 2026

Real-Time Mass Spectrometry Breath Analysis for the Investigation of Respiratory Tract Infections

An interventional study of Breath analysis in Respiratory Tract Infections (RTI), sponsored by Hopital Foch. Not yet recruiting at 3 sites in France. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Hopital Foch · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 49 studies in Respiratory Tract Infections with a site in France — 18 open to participants now, 18 under way, 4 of them phase 3. Respiratory Tract Infections · France.

Planned enrollment
12th of 32
450 · median 301
Started
2026
with 11 others
No phase
18 of 49
8 open now
Primary completion
2027-12
later than 10 of 17 live
Registered
48th of 49
by date

Among the 49 studies in Respiratory Tract Infections with a site in France, this one is the 12th largest by planned enrollment of the 32 interventional ones that give a count, is one of 12 that started in 2026, is one of 18 with no phase, reaches primary completion later than 10 of the 17 other live ones, and was the 48th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

18 of the 49 studies in Respiratory Tract Infections with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 1 Month and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Respiratory Tract Infections with a site in France, or all of them as a file.
02

Study summary

Lower respiratory tract infections (LRTIs) remain a major global health burden, with diagnosis often challenged by clinical heterogeneity, overlapping symptoms, difficulty in obtaining quality biological specimens and limitations of conventional microbiological testing. Exhaled breath contains thousands of volatile organic compounds (VOCs), arising from both host metabolism and microbial activity, and provides a non-invasive window into the metabolic landscape of infection. Emerging evidence from in vitro studies, animal models, and clinical investigations supports the existence of pathogen-specific VOC signatures. However, most published studies have relied on offline methods, such as gas chromatography-mass spectrometry (GC-MS), and robust proof-of-concept for real-time, bedside analysis in diverse, real-world populations is lacking. Proton transfer reaction-mass spectrometry (PTR-MS) offers rapid, quantitative, and non-invasive assessment of breath VOCs in both spontaneously breathing and mechanically ventilated patients.

03

Conditions studied

  • Respiratory Tract Infections (RTI)

Keywords

  • Lower respiratory tract infections
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged > 1 month, either spontaneously breathing or intubated and mechanically ventilated
  • Having suspected lower respiratory tract infection (dyspnea or tachypnea or cough or sputum production or fever or decreased breath sounds on auscultation or any other suspicious diagnostic test (imaging, blood analysis)) or previously documented chronic airway colonization
  • Willing to provide and affiliated with a health insurance system

Exclusion criteria

Exclusion Criteria:

  • Patients or representative unable to provide
  • Persons under guardianship or curatorship or persons deprived of liberty
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Breath analysis

    Breath analysis and respiratory sample collection

    Diagnostic Test: Breath analysis

Interventions

  • Diagnostic testBreath analysis

    breath sampling and collection and analysis (microscopic analysis, cultures and syndromic panel of a respiratory sample

06

What researchers measure

Primary outcomes

  1. Infection test

    Breath VOC signature for patient categorical classification of LRTI (infection / colonization / none)

    Time frame: Day 0

Secondary outcomes

  1. Pathogen class test

    Breath VOC signature differentiating bacterial and viral infections

    Time frame: Day 0

  2. Pathogen ID test

    Breath VOC signature differentiating major respiratory pathogens

    Time frame: Day

  3. Diagnostic performance

    Sensitivity, specificity, negative predictive value, positive predictive value, area under the ROC curve, accuracy of each test compared to reference standards

    Time frame: Day 0

  4. Antimicrobial susceptibility test

    Breath VOC signature differentiating susceptibility and resistance of a given pathogen to a given antibiotic (exploratory outcome).

    Time frame: Day 0

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.

Of 119 non-industry interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 18 months is above that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 6, 2026
StartEst.
Jun 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07685275
Lead sponsor
Hopital Foch
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 30, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Stanislas Grassin Delyle
Contact
s.grassindelyle@hopital-foch.com
+33 1 46 25 73 93
Virginie Guitard
Contact
drci-promotion@hopital-foch.com
+33 1 46 25 73 88

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion